Safety and Immunogenicity of a Meningococcal B Bivalent rLP2086 Vaccine in Healthy Toddlers Aged 18-36 Months: A Phase 1 Randomized-controlled Clinical Trial

Citation

Marshall, H, Richmond, P, Nissen, M et al 2012, 'Safety and Immunogenicity of a Meningococcal B Bivalent rLP2086 Vaccine in Healthy Toddlers Aged 18-36 Months: A Phase 1 Randomized-controlled Clinical Trial', The Pediatric Infectious Disease Journal, vol. 31, no. 10, pp. 1061-1068.

Year

2012

Field of Research

  • Paediatrics

Updated:  19 May 2024 / Responsible Officer:  Director (Research Services Division) / Page Contact:  Researchers